# Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

> **NCT00667121** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 88 (actual)

## Conditions studied

- Breast Cancer
- Depression
- Hot Flashes
- Psychosocial Effects of Cancer and Its Treatment

## Interventions

- **DRUG:** citalopram hydrobromide
- **DRUG:** escitalopram oxalate
- **DRUG:** gabapentin
- **DRUG:** sertraline hydrochloride
- **DRUG:** tamoxifen citrate
- **DRUG:** venlafaxine
- **GENETIC:** molecular genetic technique
- **OTHER:** high performance liquid chromatography
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00667121
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-16
- **Primary completion:** 2014-05-12
- **Final completion:** 2014-05-27
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667121, "Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00667121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*